Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Rani Therapeutics Holdings (RANI) Long-Term Debt Issuances (2020 - 2022)

Rani Therapeutics Holdings has reported Long-Term Debt Issuances over the past 3 years, most recently at $14.9 million for Q4 2022.

  • Quarterly results put Long-Term Debt Issuances at $14.9 million for Q4 2022, up 766.45% from a year ago — trailing twelve months through Dec 2023 was $29.6 million (changed 0.0% YoY), and the annual figure for FY2022 was $29.6 million, up 1619.42%.
  • Long-Term Debt Issuances for Q4 2022 was $14.9 million at Rani Therapeutics Holdings, up from $14.7 million in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for RANI hit a ceiling of $14.9 million in Q4 2022 and a floor of -$1.7 million in Q3 2021.
  • Median Long-Term Debt Issuances over the past 3 years was $1.7 million (2021), compared with a mean of $5.2 million.
  • Biggest five-year swings in Long-Term Debt Issuances: skyrocketed 1002.56% in 2021 and later surged 766.45% in 2022.
  • Rani Therapeutics Holdings' Long-Term Debt Issuances stood at $156000.0 in 2020, then skyrocketed by 1002.56% to $1.7 million in 2021, then surged by 766.45% to $14.9 million in 2022.
  • The last three reported values for Long-Term Debt Issuances were $14.9 million (Q4 2022), $14.7 million (Q3 2022), and $1.7 million (Q4 2021) per Business Quant data.